Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03756558 · ClinicalTrials.gov registry record · NA
Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System
A NA study, sponsored by Terumo Medical Corporation.
- Completed
- Registry status
- NA
- Development phase
- 147
- Enrollment target
NCT03756558: Completed NA study, sponsored by Terumo Medical Corporation.
NCT03756558 is a NA study that has completed, run by Terumo Medical Corporation. The registered enrollment target is 147 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03756558, a NA study, has completed, sponsored by Terumo Medical Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 147 participants
- Enrollment target
Study Summary
This study evaluates the safety and effectiveness of the Cross-Seal vascular closure device in gaining post procedure hemostasis in subjects undergoing interventional procedures requiring an 8 to 18 french size introducer sheath.
Primary Outcome
Freedom from major complications of the target limb. Major Complications include: access site vascular injury that requires surgical intervention, access related lower extremity ischemia, access site infection
Interventions
- DEVICE Cross-Seal System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2019-08-09 |
| Est. Completion | 2021-03-22 |
| Phase | NA |
What the finished NCT03756558 record still lists
NCT03756558 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Cross-Seal System is the first listed.
NCT03756558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03756558 about?
NCT03756558 is a clinical study titled "Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System". This study evaluates the safety and effectiveness of the Cross-Seal vascular closure device in gaining post procedure hemostasis in subjects undergoing interventional procedures requiring an 8 to 18 french size introducer sheath.
What is the current status of trial NCT03756558?
This trial is currently completed. It is a NA study. The enrollment target is 147 participants. The study started on 2019-08-09. Estimated completion is 2021-03-22.
What interventions are being tested in trial NCT03756558?
The interventions under investigation include: Cross-Seal System (DEVICE).
Who is sponsoring clinical trial NCT03756558?
This trial is sponsored by Terumo Medical Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03756558's enrollment target sits among peer trials
147 703rd of 2000 higher than 1,297 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI